Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4041543 | 1.00 | HSD11B1 (0.33) | HSD11B1HCRTR2NR1H2GPR119PREP | |
| SCHEMBL22950789 | 0.87 | GPR119 (0.38) | HSD11B1GPR119 | |
| SCHEMBL22950853 | 0.82 | PREP (0.35) | NR1H2PREPLMNANPSR1CTSK | |
| SCHEMBL4045705 | 0.81 | GPR119 (0.37) | HSD11B1NR1H2GPR119PREPNR1H3 | |
| SCHEMBL24821656 | 0.80 | NR1H2 (0.42) | HSD11B1NR1H2PREPLMNANPSR1 | |
| SCHEMBL1639634 | 0.80 | NR1H2 (0.42) | HSD11B1NR1H2PREPLMNANPSR1 | |
| SCHEMBL2227084 | 0.80 | NR1H2 (0.42) | HSD11B1NR1H2PREPLMNANPSR1 | |
| SCHEMBL17137099 | 0.78 | ALDH1A1 (0.35) | PREPLMNANPSR1CTSK | |
| SCHEMBL17137102 | 0.78 | ALDH1A1 (0.35) | PREPLMNANPSR1CTSK | |
| SCHEMBL24909113 | 0.78 | ALDH1A1 (0.35) | PREPLMNANPSR1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | HSD11B1 832/4885HCRTR2 1558/4885NR1H2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.